| Valuation method | Value, € | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 36.64 | 129 |
| Intrinsic value (DCF) | 6.42 | -60 |
| Graham-Dodd Method | 8.65 | -46 |
| Graham Formula | 6.93 | -57 |
Medios AG is a leading German specialty pharmaceutical wholesaler, focusing on high-value medications for complex conditions such as oncology, neurology, and autoimmunology. Founded in 2016 and headquartered in Berlin, the company operates through two key segments: Pharmaceutical Supply, which distributes specialty drugs, and Patient-Specific Therapies, which provides customized medication solutions for pharmacies and patients. Medios AG plays a critical role in Germany's healthcare supply chain, ensuring access to vital treatments while leveraging its expertise in niche therapeutic areas. With a revenue of €1.88 billion (2024), the company has established itself as a key player in the medical distribution sector. Its strong cash position (€106 million) and strategic focus on high-margin specialty pharmaceuticals position it well for sustainable growth in Europe's evolving healthcare landscape.
Medios AG presents a mixed investment profile. On the positive side, the company operates in the stable and growing specialty pharmaceutical distribution sector, with a strong presence in Germany. Its focus on high-margin therapies and patient-specific solutions provides a competitive edge. However, investors should note the company's relatively low net income margin (0.67%) and significant debt (€238 million), which could pose risks in a rising interest rate environment. The stock's beta of 1.2 suggests higher volatility than the market. While the lack of dividends may deter income-focused investors, Medios AG's strong operating cash flow (€73.7 million) and niche market positioning could appeal to growth-oriented investors betting on Germany's pharmaceutical sector.
Medios AG competes in the highly regulated German pharmaceutical distribution market, where its key advantages include specialization in high-value specialty drugs and patient-specific therapies. Unlike general pharmaceutical wholesalers, Medios focuses on complex therapies with higher barriers to entry, allowing for better margins. The company's 2016 founding gives it a more agile structure compared to older competitors, enabling faster adaptation to market changes. However, its relatively small scale (€1.88 billion revenue) limits purchasing power compared to pan-European distributors. Medios' strength in patient-specific therapies provides differentiation, as this segment requires specialized manufacturing capabilities that general distributors typically lack. The company's German focus is both a strength (deep local market knowledge) and a weakness (limited geographic diversification). Its balance sheet shows adequate liquidity but carries meaningful debt, which could constrain growth ambitions compared to better-capitalized rivals. The competitive landscape is intensifying as larger players expand into specialty pharmaceuticals, potentially pressuring margins.